Contract for the provision of Histopathology Reporting

Location

The Poundbury Cancer Institute<br/>Newborough House<br/>3 Queen Mother Square<br/>Poundbury<br/>Dorchester<br/>DT1 3BJ

Description

Contract for the provision of Histopathology Reporting

Total Quantity or Scope

This is a direct award to the incumbent supplier Poundbury Cancer Institute, under the Provider Selection Regime (PSR) using Process C. The contract is for the provision of outsourced histopathology reporting. The contract term is from 01/08/2026 to 31/03/2027 (with a 3 month termination notice clause by either party). This is a variable contract with no guarantee of volume or value. The estimated value is £237,528 based on previous spend. An option to extend for a further 3 months has been included, if the incumbent supplier can demonstrate it still meets the required service level criteria and fulfils the guidelines associated with Process C. As shown in the disclosed criteria, the main criterion is Quality. "Quality and Innovation" is weighted at 50% as the key objective is maintaining a high-quality service. The other elements of quality-led criteria total a further 40% of the weighting. Value in terms of cost has been weighted 10%, because maintaining the quality of the service is the main objective of this award. The Trust has measured the incumbent supplier's current and likely future performance against the criteria and confirm their recommendation to make a direct award via Process C.

Award Detail

Award Criteria

CPV Codes

• 85111800 - Pathology services

Indicators

• Award on basis of price and quality.

Legal Justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by 27/08/26. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR'. Any representations should be forwarded to christine.chambers3@nhs.net and sarah.ogungbe@nhs.net. The award decision makers are Matthew Long - Laboratory Manager of Histopathology (GWH) and Rob Webb, Director of Procurement for BSW Alliance, on behalf of Great Western Hospital NHS Foundation Trust (GWH). There are not any conflicts of interest and the Trust can demonstrate a clear and transparent application of the service criteria during their decision process. The decision process was based on a review of the incumbant supplier's performance against a set of 5 criteria with a total weighting of 100% as published.

Other Information

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt,the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill process. Representations by providers must be made to the relevant authority by 27/08/26. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR. Great Western Hospital NHS Foundation Trust (GWH) intends to observe a standstill period of 8 working days as per the guidelines. Once this is completed, subject to a non-receipt of representation from other providers, the contract will be awarded. Written representations should be sent to christine.chambers3@nhs.net and sarah.ogungbe@nhs.net